Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.

15 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $51.15 in the next year. This suggests a possible upside of 105.2% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR shares have decreased by 38.5% and is now trading at $24.93.
View the best growth stocks for 2023 here.

Arrowhead Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,880,000 shares, an increase of 9.9% from the October 31st total of 7,170,000 shares. Based on an average daily trading volume, of 995,100 shares, the short-interest ratio is presently 7.9 days. Approximately 7.8% of the company's stock are short sold.
View Arrowhead Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our ARWR earnings forecast.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analyst estimates of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 85.27%. Arrowhead Pharmaceuticals's revenue was down 51.2% on a year-over-year basis. During the same period last year, the firm earned ($0.68) earnings per share.

ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Neuberger Berman Disrupters ETF (NBDS), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and AI Powered Equity ETF (AIEQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.02%), JPMorgan Chase & Co. (2.60%), Invesco Ltd. (2.28%), Northern Trust Corp (1.18%), Avidity Partners Management LP (0.99%) and Bank of New York Mellon Corp (0.92%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.